MRK logo

Merck & Co., Inc.

MRK
Healthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89

Clinical Trials (768)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT06658522
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I
P4
Recruiting20Open-labelSotatercept
NCT05992480
REVIVE (Response to the Ebola Virus Vaccine)
Ebola Virus Disease
P4
Active40Open-labelrVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)
NCT05911295
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Urothelial Carcinoma
P3
Active412RCT, Open-labeldisitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
NCT03682536
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Myelodysplastic Syndromes
P3
Active363RCT, Open-labelLuspatercept, Epoetin alfa
NCT07159763
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza
P3
Recruiting10,000RCT, Double-blind—
NCT01252953
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
Atherosclerotic Cardiovascular Disease
P3
Active30,449RCT, Double-blindAnacetrapib, Placebo anacetrapib
NCT04624204
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Small Cell Lung Cancer
P3
Active672RCT, Double-blindPembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice
NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
P3
Recruiting590RCT, Open-labelSacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy
NCT04586231
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
P3
Active747RCT, Open-labelBelzutifan, Lenvatinib, Cabozantinib
NCT04924608
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Neurofibromatosis 1, Plexiform Neurofibroma (PN)
P3
Active145RCT, Double-blindSelumetinib
NCT06136585
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Neuromuscular Blocks
P3
Recruiting80RCT, Double-blind2 mg/kg sugammadex, 0.07 mg/kg neostigmine
NCT03725059
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Breast Cancer
P3
Active1,240RCT, Double-blindPembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy
NCT02811861
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Renal Cell Carcinoma
P3
Active1,069RCT, Open-labelLenvatinib, Everolimus, Pembrolizumab, Sunitinib
NCT03765918
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Head and Neck Neoplasms
P3
Active714RCT, Open-labelPembrolizumab 200 mg, Cisplatin 100 mg/m^2
NCT05722015
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
Metastatic Non-small Cell Lung Cancer
P3
Active377RCT, Open-labelPembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim
NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
P3
Recruiting1,530RCT, Open-labelPembrolizumab, Sacituzumab tirumotecan, Capecitabine
NCT06052059
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Ulcerative Colitis
P3
Active1,109RCT, Double-blindIV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
NCT03401788
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation
P2
Active50Open-labelBelzutifan
NCT07225959
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
Healthy Participants
P2
Active400Open-label—
NCT04262141
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
Essential Thrombocythemia, Polycythemia Vera
P2
Active4Open-labelIMG-7289
NCT03634540
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC)
P2
Active118Open-labelBelzutifan, Cabozantinib
NCT04081220
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
Thrombocythemia, Essential
P2
Active9Open-labelIMG-7289
NCT04143724
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Beta-Thalassemia
P2
Recruiting99Open-labelACE-536
NCT05270525
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Pulmonary Disease, Chronic Obstructive, COPD
P2
Active70RCT, Double-blindEnsifentrine, Placebo, LABA/LAMA
NCT05270668
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
P2
Active154RCT, Double-blindTulisokibart, Placebo
NCT06559150
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
P2
Recruiting284RCT, Double-blindNebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
P1P2
Active190Open-labelNemtabrutinib
NCT06163430
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
P1P2
Recruiting330RCT, Open-labelMK-4208
NCT04471727
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
P1P2
Active232Open-labelGocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
NCT06100913
Immunology of Ebola Vaccine
Ebola Virus Disease
P2
Active30Open-labelRecombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)
NCT06809140
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Muscle Invasive Bladder Urothelial Carcinoma
P2
Recruiting75Open-labelEnfortumab vedotin, Pembrolizumab
NCT04145622
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Advanced Solid Tumor, Malignant Solid Tumor
P1P2
Active247Open-labelIfinatamab deruxtecan (I-DXd)
NCT03414229
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Sarcoma
P2
Active30Open-labelEpacadostat, Pembrolizumab
NCT04869137
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin
P2
Active26Open-labelLenvatinib Oral Product, Pembrolizumab
NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
P1P2
Recruiting340RCT, Single-blindINBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
NCT05366166
Pembrolizumab Plus Olaparib in LA-HNSCC
Squamous Cell Carcinoma of Head and Neck
P2
Active45Open-labelPembrolizumab, Olaparib, Cisplatin
NCT04920617
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
P2
Recruiting102RCT, Open-labelDPX-Survivac, Pembrolizumab, CPA
NCT03747120
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
HER2-positive Breast Cancer, Breast Cancer
P2
Active138RCT, Open-labelPaclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab
NCT05025813
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer
P2
Recruiting27Open-labelPembrolizumab
NCT04471974
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
P2
Active61Open-labelBET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab
NCT07222488
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Bladder Cancer, Urinary Bladder Neoplasms
P1P2
Recruiting45Open-labelMK-3120
NCT05221645
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
P2
Active65RCT, Open-labelPembrolizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
NCT04980872
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
P2
Active60Open-labelMiransertib
NCT04956640
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
P1P2
Active540Open-labelLY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
NCT05879146
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Tumor
P2
Recruiting40Open-labelNirogacestat
NCT06979596
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Malignant Neoplasm
P2
Recruiting250RCT, Single-blindOpevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole
NCT07463183
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Colitis Ulcerative, Ulcerative Colitis
P2
Recruiting100RCT, Double-blindMK-8690
NCT03153202
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
P1P2
Active23Open-labelIbrutinib, Pembrolizumab
NCT04421560
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Primary Central Nervous System Lymphoma, Recurrent Cancer
P1P2
Recruiting37Open-labelIbrutinib, Pembrolizumab, Rituximab
NCT02858921
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Melanoma
P2
Active60RCT, Open-labelDabrafenib, Trametinib, Pembrolizumab
NCT05147558
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
P2
Active40Open-labelPembrolizumab, Lenvatinib
NCT03485209
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
P2
Active350Open-labeltisotumab vedotin, pembrolizumab, carboplatin, cisplatin
NCT06340711
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
P2
Recruiting27Open-labelOBP-301, Pembrolizumab
NCT06976944
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Recurrent Triple-Negative Breast Cancer
P2
Recruiting24RCT, Open-labelPembrolizumab, Paclitaxel, Bevacizumab
NCT03989089
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
HER2-Negative Breast Cancer
P2
Active44Open-labelPembrolizumab
NCT06307431
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Renal Cell Carcinoma
P2
Active272RCT, Double-blindIntismeran autogene, Pembrolizumab, Placebo
NCT06956235
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Hidradenitis Suppurativa
P2
Active149RCT, Double-blindTulisokibart, Placebo
NCT02998268
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
P2
Active42RCT, Open-labelPembrolizumab, Taxol, Carboplatin
NCT03618550
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
P2
Recruiting257Open-labelpembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin
NCT07221474
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Squamous Non-small Cell Lung Cancer
P2
Recruiting180RCT, Double-blindIntismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
NCT03504163
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Bladder Cancer
P2
Active45Open-labelPembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG)
NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
P2
Active189RCT, Open-labelZilovertamab vedotin, Nemtabrutinib
NCT05394103
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Advanced Cancer, Metastatic Cancer
P1P2
Recruiting130Open-labelQ901, KEYTRUDA® (pembrolizumab)
NCT04438213
Ertugliflozin in Chronic Heart Failure
Heart Failure
P2
Recruiting60RCT, Double-blindErtugliflozin, Metolazone, Placebo
NCT05597306
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
P1
Recruiting18Open-labelBomedemstat, Venetoclax
NCT02974738
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Advanced Solid Tumors, Solid Tumor
P1
Active120Open-labelBelzutifan
NCT02293980
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
ccRCC, RCC
P1
Active110Open-labelMK-3795, Nivolumab, Cabozantinib, Bezlutifan
NCT07300085
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Healthy Participants
P1
Recruiting710RCT, Double-blindFluzone® High-Dose (HD) influenza vaccine
NCT04184050
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Multiple Myeloma in Relapse, Multiple Myeloma
P1
Active100Open-labelMK-4002
NCT03260491
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
P1
Active312Open-labelHER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
NCT07712575
A Study of V132 in Healthy Older Participants (V132-001)
Healthy
P1
Recruiting280RCT, Double-blindV132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™
NCT02560636
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
Invasive Bladder Cancer
P1
Active34Open-labelPembrolizumab
NCT06540391
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
Melanoma
P1
Active41RCT, Open-labelMB097, Pembrolizumab, Vancomycin
NCT00404989
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
HIV Infections, Hepatitis B
Recruiting24,258——
NCT01731353
FungiScope - A Global Emerging Fungal Infection Registry
Invasive Fungal Disease
Recruiting1,000——
NCT02438631
Placental Passage and Disposition of Drugs: A Physiology-based Approach
Pregnancy
Recruiting2,000——
NCT06036810
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
Ovarian Cancer
N/A
Recruiting70Open-label—
NCT06681077
A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York
Healthy
N/A
Recruiting500RCT, Double-blind—
NCT05467917
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
COVID-19, Households
Active374——
NCT00414115
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
Adverse Drug Reaction (ADR)
Recruiting7,000——
NCT05376891
Met Non Small Cell Cancer Registry (MOMENT)
Cancer
Recruiting700——
NCT01818141
Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
Clostridium Difficile Infection
P4
Completed34RCT, Open-labelVancomycin, Fidaxomicin
NCT01775397
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
Clostridium Difficile
P4
Terminated12RCT, Double-blindFidaxomicin, Vancomycin, Placebo
NCT00572260
A Pilot Study of Daptomycin for Antimicrobial Prophylaxis
Antimicrobial Prophylaxis
P4
Terminated11Open-labeldaptomycin 6 mg/kg IV
NCT00638157
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
Infective Endocarditis
P4
Terminated24RCT, Double-blinddaptomycin, daptomycin and gentamicin
NCT01175707
Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting
Complicated Skin or Skin Structure Infection
P4
Terminated80RCT, Open-labelDaptomycin, Vancomycin
NCT00102947
Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections
Soft Tissue Infections
P4
Terminated72RCT, Open-labeldaptomycin (up to 14 days)
NCT00295178
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
Cellulitis
P4
Completed80RCT, Single-blindDaptomycin, Vancomycin
NCT00651131
Cubicin(R) for Complicated Post-surgical Wound Infections
Wound Infections
P4
Terminated69RCT, Open-labeldaptomycin
NCT01133600
Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens
Diabetic Foot
P4
Terminated6RCT, Open-labelCubicin, Vancomycin
NCT00711802
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
Skin Diseases, Infectious
P4
Completed396RCT, Single-blindDaptomycin, Standard of Care (SOC)
NCT00663403
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
Critically Ill, Hemodialysis
P4
Completed8Open-labelDaptomycin
NCT02355938
Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
Clostridium Difficile, Spinal Cord Injury
P4
Terminated12RCT, Double-blindFidaxomicin 200 mg, Placebo, Vancomycin
NCT01728376
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Bacteremia
P4
Completed82RCT, Open-labelDaptomycin, Comparator
NCT01419184
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
Staphylococcal Skin Infections
P4
Completed250RCT, Open-labelDaptomycin, Vancomycin
NCT01287832
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
Bacteremia
P4
Terminated11RCT, Open-labelVancomycin, Daptomycin
NCT00708201
A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy
Postoperative Ileus
P4
Completed280RCT, Double-blindAlvimopan, Placebo
NCT02421120
Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
P4
Completed21Open-labelCeftolozane/Tazobactam
NCT01104662
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia
P4
Terminated92RCT, Single-blindVancomycin, Daptomycin, Semi-Synthetic Penicillin
NCT01196169
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
P4
Terminated28RCT, Open-labelDaptomycin, Vancomycin
NCT01142466
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Multiple Sclerosis, Relapsing-Remitting
P4
Completed30RCT, Open-labelInterferon beta-1a (Rebif)
NCT00629941
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
Blepharitis
P4
Completed25Open-labelAzaSite®
NCT00833027
ALPHA Sitagliptin Add on to Metformin (0431-103)
Diabetes Mellitus
P4
Completed608Open-labelsitagliptin phosphate
NCT05061654
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Neutropenia, Febrile, Hematologic Cancer
P4
Withdrawn—Open-labelCeftolozane-tazobactam IV
NCT03170661
Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions.
Surgical Conditions
P4
Completed98RCT, Double-blindDeep neuromuscular block
NCT07706166
Letermovir for R+ Study
Kidney Transplant, Liver Transplant
P4
Not Yet Recruiting146Open-labelLetermovir
NCT03002506
Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
Burns, Pharmacokinetics
P4
Terminated6Open-labelCeftolozane/tazobactam
NCT02704754
Suvorexant and Trauma Related Insomnia
Insomnia, Posttraumatic Stress Disorder
P4
Completed41RCT, Double-blindsuvorexant
NCT00202839
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
Hepatitis C, Chronic
P4
Completed160RCT, Open-labelPegIntron (peginterferon alfa-2b; SCH 54031), PegIntron (peginterferon alfa-2b; SCH 54031), Ribavirin, Ribavirin
NCT00656539
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
Blepharitis
P4
Completed20RCT, Open-labelAzaSite®
NCT00721240
Investigation to Identify Predictors of Response to a Treatment With Montelukast
Asthma
P4
Completed50Open-labelmontelukast
NCT03111108
Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)
Hepatitis C Virus (HCV) Infection
P4
Completed117RCT, Open-labelEBR/GZR (50 mg/100 mg) FDC
NCT01549041
Once-Daily Asenapine for Schizophrenia
Schizophrenia
P4
Completed30RCT, Open-labelAsenapine 10 mg daily in the evening, Asenapine 5 mg twice daily
NCT00157690
Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
Cystic Fibrosis, Osteoporosis
P4
Completed56RCT, Double-blindAlendronate, Placebo
NCT00708539
A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.
IVF - Luteal Phase Support After Embryo Transfer
P4
Unknown2,686RCT, Single-blindprogesterone, Progesterone
NCT00575380
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
Bacterial Infections, Eye Infections
P4
Completed116RCT, Open-labelAzaSite Eye Drops, Vigamox Eye Drops
NCT02484651
Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
Neuromuscular Block
P4
Completed70RCT, Open-labelSugammadex, Rocuronium
NCT02342418
Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults
Obesity
P4
Completed19Open-labelTedizolid phosphate
NCT00781287
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
Human Immunodeficiency Virus
P4
Terminated10RCT, Open-label3-drug anti-HIV therapy, Raltegravir
NCT01926015
Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)
Rotavirus Disease
P4
Completed192RCT, Open-labelRotaTeq™ (V260), DTP-IPV
NCT04334551
HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance
HIV Infections
P4
Unknown40Open-labelDoravirine
NCT01025765
The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin
Chronic Hepatitis C
P4
Unknown80RCT, Open-labelPioglitazone, Acarbose, Metformin
NCT01667107
A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)
Fungal Infection
P4
Terminated26Open-labelPosaconazole, Calogen®
NCT01148901
Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)
Ankylosing Spondylitis
P4
Withdrawn—Open-labelInfliximab
NCT00520234
Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
P4
Completed222RCT, Double-blindCaspofungin, Normal Saline
NCT03381859
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
Hepatitis C Virus Infection, Response to Therapy of
P4
Withdrawn—Open-labelElbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
NCT02406443
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Type 2 Diabetes
P4
Completed36RCT, Double-blindSitaglitpin
NCT01727271
A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)
Hepatitis B
P4
Withdrawn—RCT, Open-labelTenofovir, Pegylated interferon alpha-2b
NCT01027806
Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children
Obstructive Sleep Apnea
P4
Terminated64RCT, Double-blindMontelukast
NCT05289271
Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)
Vaccines, Combined, Hexavalent Vaccine
P4
Completed168Open-labelVaxelis™
NCT01871532
Low-dose Gonal-f® in Ovulation Induction
Infertility, Monofollicular Development
P4
Terminated24RCT, Open-labelGonal-f®
NCT00265252
Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis
Non-Traumatic Osteonecrosis
P4
Unknown60RCT, Double-blindAlendronate
NCT00466401
Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation
Hypercholesterolemia
P4
Completed20Open-labelSimvastatin, Ezetimibe
NCT00993187
Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
Type 2 Diabetes Mellitus
P4
Completed292RCT, Double-blindSitagliptin/Metformin FDC, Comparator: Glimepiride, Matching placebo to Sitagliptin/Metformin FDC, Matching placebo to glimepiride
NCT00650663
Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)
Hypercholesterolemia, Atherosclerosis
P4
Completed247RCT, Double-blindEzetimibe + Simvastatin, Simvastatin
NCT00157898
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
Complicated Intra-abdominal Infection
P4
Completed134RCT, Open-labelMK0826; ertapenem sodium, Comparator: ceftriaxone + metronidazole
NCT00119015
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis
Rhinitis, Allergic, Perennial
P4
Terminated102RCT, Double-blindPlacebo, Montelukast, Fluticasone propionate
NCT01364090
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Hepatitis C, Chronic
P4
Completed93Open-labelPegylated interferon alfa 2b, Ribavirin
NCT01173510
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
HIV Infections, Acquired Immune Deficiency Syndrome
P4
Withdrawn—RCT, Open-labelRaltegravir plus Truvada, Atripla
NCT01364298
Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management
Diabetic Peripheral Neuropathic Pain
P4
Completed353RCT, Open-labelGabapentin/B-complex, Pregabalin
NCT03420300
EBR/GZR for HCV-1b Patients Receiving Hemodialysis
Hepatitis C
P4
Completed40Open-labelEBR/GZR
NCT00939874
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
HIV, Osteopenia
P4
Completed52Open-labelRaltegravir
NCT00686725
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Glioblastoma
P4
Completed99RCT, Open-labelTemozolomide
NCT01419249
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
Idiopathic Growth Hormone Deficiency, Turner Syndrome
P4
Completed458Open-label—
NCT00910689
Drug and Non-Drug Treatment Of Severe Migraine
Migraine Headache
P4
Completed232RCT, Double-blindPropranolol or nadolol, Placebo control, Optimal Acute Therapy
NCT03351608
Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)
Neuromuscular Blockade
P4
Completed288RCT, Double-blindSugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
NCT00348855
Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice
High Risk Hypertensive Patients
P4
Completed1,836RCT, Single-blind—
NCT00934713
The Effect of Montelukast Treatment in Wheezy Infants
Lung Disease, Obstructive, Signs and Symptoms, Respiratory
P4
Completed112RCT, Double-blindmontelukast
NCT03520959
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Synovial Sarcoma, Cancer
P3
Terminated1RCT, Double-blindLV305, G305
NCT00540072
Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
Pneumonia, Bacterial
P3
Completed—RCT, Double-blinddaptomycin
NCT00468728
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Clostridium Infections, Diarrhea
P3
Completed535RCT, Double-blindPAR-101/OPT-80, Vancomycin
NCT00241722
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Bowel Dysfunction, Constipation
P3
Completed805RCT, Double-blindAlvimopan, Placebo
NCT00701636
Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery
Late Effects of Surgery, Staphylococcus Aureus
P3
Completed30Open-labeldaptomycin
NCT03667690
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Candidemia, Mycoses
P3
Completed199RCT, Double-blindRezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
NCT04896008
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
Pulmonary Arterial Hypertension
P3
Completed173RCT, Double-blindSotatercept
NCT04576988
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
Pulmonary Arterial Hypertension
P3
Completed324RCT, Double-blindSotatercept, Placebo, Background PAH Therapy
NCT02631070
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Myelodysplastic Syndromes
P3
Completed229RCT, Double-blindLuspatercept
NCT00055198
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
Gram-Positive Bacterial Infections
P3
Terminated75Open-labeldaptomycin
NCT00388479
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus
Ileus
P3
Completed666RCT, Double-blindAlvimopan
NCT01216241
Daptomycin Versus Placebo in Patients With Neutropenia and Fever
Febrile Neutropenia
P3
Terminated36RCT, Double-blindDaptomycin, Daptomycin
NCT01691248
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)
Clostridium Difficile-Associated Diarrhea (CDAD)
P3
Completed611RCT, Double-blindfidaxomicin, Placebo
NCT00443690
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy
Heart Failure, Congestive
P3
Completed480RCT, Double-blindrolofylline, Comparator: Placebo (unspecified)
NCT01901328
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Opioid-Induced Constipation
P3
Terminated49RCT, Double-blindCB-5945, Placebo
NCT01345929
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
Complicated Urinary Tract Infection, Pyelonephritis
P3
Completed558RCT, Double-blindCXA-201, Levofloxacin
NCT04095858
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease
P3
Terminated11RCT, Double-blindEfprezimod alfa, Placebo, Methotrexate, Tacrolimus
NCT00314951
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
Clostridium Infections, Diarrhea
P3
Completed629RCT, Double-blindFidaxomicin, Vancomycin, Matching Placebo to Fidaxomicin
NCT01170221
TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
Skin and Subcutaneous Tissue Bacterial Infections
P3
Completed667RCT, Double-blindTR-701 FA, Linezolid
NCT00256932
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Bowel Dysfunction, Constipation
P3
Completed518RCT, Double-blindalvimopan, Placebo
NCT04317040
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Coronavirus Disease 2019 (COVID-19)
P3
Completed234RCT, Double-blindEfprezimod alfa, Placebo
NCT01853982
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
Ventilator-Associated Pneumonia (VAP)
P3
Terminated4RCT, Open-labelCeftolozane/Tazobactam, Piperacillin/Tazobactam
NCT00093067
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
Bacterial Endocarditis, Bacteremia
P3
Completed—RCT, Open-labeldaptomycin
NCT02604433
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
Erythrocyte Transfusion, Beta-Thalassemia
P3
Completed336RCT, Double-blindLuspatercept
NCT02019420
Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
Pneumonia
P3
Completed726RCT, Double-blindTedizolid phosphate, Linezolid
NCT00388258
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Ileus
P3
Completed451RCT, Double-blindAlvimopan
NCT01755767
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Hepatocellular Carcinoma
P3
Completed383RCT, Double-blindTivantinib, Placebo
NCT02276482
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
Skin Diseases, Infectious, Skin Diseases, Bacterial
P3
Completed120RCT, Single-blindTedizolid Phophate, Antibiotic comparator, Aztreonam, Metronidazole
NCT01597505
Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Clostridium Difficile Infection
P3
Completed606RCT, Double-blindSurotomycin, Vancomycin, Placebo
NCT04535986
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Chronic Obstructive Pulmonary Disease
P3
Completed763RCT, Double-blindEnsifentrine, Placebo
NCT01445678
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
Complicated Intra-abdominal Infection
P3
Completed494RCT, Double-blindCXA-201 and metronidazole, Meropenem
NCT00205842
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Ileus
P3
Completed660RCT, Double-blindalvimopan
NCT06460493
Effect of Ensifentrine Treatment on CAT Score
COPD
P3
Completed20Open-labelEnsifentrine 3 mg twice daily
NCT02070757
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia
P3
Completed726RCT, Double-blindCeftolozane/tazobactam, Meropenem
NCT00354458
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
Heart Failure, Congestive
P3
Completed1,102RCT, Double-blindrolofylline, Comparator: Placebo (unspecified)
NCT01421511
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections
P3
Completed666RCT, Double-blindTR-701 FA, Linezolid
NCT01922011
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Acute Hematogenous Osteomyelitis
P3
Completed149RCT, Double-blindDaptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent)
NCT04542057
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Chronic Obstructive Pulmonary Disease
P3
Completed790RCT, Double-blindEnsifentrine, Placebo
NCT01696643
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Opioid-Induced Constipation
P3
Terminated1,407RCT, Double-blindCB-5945, Placebo
NCT00388401
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Ileus
P3
Completed510RCT, Double-blindAlvimopan
NCT00328692
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
Heart Failure, Congestive
P3
Completed932RCT, Double-blindrolofylline, Comparator: Placebo (unspecified)
NCT01704651
Accelerating Gastrointestinal Recovery
Ovarian Cancer, Fallopian Tube Cancer
P3
Completed146RCT, Double-blindAlvimopan, Placebo
NCT00259922
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Bowel Dysfunction, Constipation
P3
Completed485RCT, Double-blindPlacebo, Alvimopan, Alviompan
NCT00538694
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Pneumonia, Bacterial
P3
Completed—RCT, Double-blinddaptomycin
NCT00448422
Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers
Acute Bacterial Gastroenteritis
P3
Completed268RCT, Double-blindprulifloxacin
NCT04811092
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Pulmonary Arterial Hypertension
P3
Terminated321RCT, Double-blindSotatercept
NCT01901341
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Opioid-Induced Constipation
P3
Terminated44RCT, Double-blindCB-5945, Placebo
NCT01598311
A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
Clostridium Difficile Infection
P3
Completed608RCT, Double-blindCB-183,315, Vancomycin, Placebo
NCT01901302
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Opioid-Induced Constipation
P3
Terminated61RCT, Double-blindCB-5945, Placebo
NCT01244191
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Non Squamous, Non-small-cell Lung Cancer
P3
Terminated1,048RCT, Double-blindTivantinib, Placebo, Erlotinib
NCT05064059
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Colorectal Cancer
P3
Completed441RCT, Open-labelfavezelimab/pembrolizumab, regorafenib, TAS-102
NCT02577003
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Type 2 Diabetes Mellitus
P3
Completed143RCT, Double-blindIpragliflozin, Placebo, Sitagliptin
NCT00876317
Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder
Soft Tissue Injuries of the Shoulder, Tenosynovitis and Bursitis Affecting the Shoulder
P3
Terminated45RCT, Double-blindEtoricoxib 60 mg, Etoricoxib 90 mg
NCT00375388
The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial
Type 2 Diabetes Mellitus
P3
Completed400RCT, Double-blindMetformin on top of intensive insulin therapy
NCT00988520
Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)
Anesthesia
P3
Completed38RCT, Open-labelRocuronium bromide, Rocuronium bromide, Rocuronium bromide, Sevoflurane, Propofol
NCT03361865
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
UC (Urothelial Cancer)
P3
Completed93RCT, Open-labelPembrolizumab, Epacadostat, Placebo
NCT00750919
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
Sleep Initiation and Maintenance Disorders, Mental Disorders
P3
Terminated184Open-labelesmirtazapine
NCT03950622
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)
Pneumococcal Infections
P3
Completed1,205RCT, Double-blindV114, Prevnar 13®
NCT00048607
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
Major Depressive Disorder
P3
Completed600RCT, Double-blindaprepitant, Comparator: paroxetine HCL, Comparator: Placebo (Unspecified)
NCT03284866
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia
P3
Completed535RCT, Double-blindRecombinant Human Papillomavirus Nonavalent Vaccine
NCT00541775
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
Type 2 Diabetes Mellitus
P3
Completed273RCT, Double-blindSitagliptin, Comparator: Rosiglitazone, Comparator: Placebo, Comparator: Metformin
NCT00124072
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
Cardiovascular Disease
P3
Completed12,064RCT, Double-blindSimvastatin 20 mg daily, Simvastatin 80 mg daily, Placebo
NCT05569954
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
Pneumococcal Disease
P3
Completed1,484RCT, Double-blindV116, PPSV23
NCT01995721
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Recurrent Respiratory Papillomatosis
P3
Unknown20Open-label4-valent HPV vaccine
NCT00358670
Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
Psoriasis
P3
Terminated441RCT, Open-labelinfliximab, infliximab
NCT00035295
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
Major Depressive Disorder
P3
Completed584RCT, Double-blindMK0869, aprepitant, Comparator: placebo
NCT00292266
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
Multiple Sclerosis, Relapsing-Remitting
P3
Completed677RCT, Open-labelRebif®, Avonex®
NCT02137772
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Prevention of CMV Infection or Disease
P3
Completed570RCT, Double-blindLetermovir, Placebo
NCT00322231
A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)
Herpes Zoster
P3
Completed101RCT, Double-blindzoster vaccine live (ZOSTAVAX™), Comparator: Placebo
NCT00449930
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
Type 2 Diabetes Mellitus
P3
Completed1,050RCT, Double-blindsitagliptin phosphate, Comparator: metformin hydrochloride
NCT00564460
On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)
Benign Prostatic Hyperplasia
P3
Withdrawn—RCT, Double-blindFinasteride, Placebo
NCT02625623
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
P3
Completed371RCT, Open-labelAvelumab, Irinotecan, Paclitaxel
NCT02576574
Avelumab in First-line NSCLC (JAVELIN Lung 100)
First Line Non-Small Cell Lung Cancer
P3
Completed1,214RCT, Open-labelAvelumab, Pemetrexed, Paclitaxel, Gemcitabine, Gemcitabine, Carboplatin, Cisplatin, Carboplatin, Avelumab Weekly
NCT00535288
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
Postmenopausal Symptoms, Menopause
P3
Completed946RCT, Double-blindEsmirtazapine, Placebo
NCT03260894
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Renal Cell Carcinoma (RCC)
P3
Completed129RCT, Open-labelPembrolizumab, Epacadostat, Sunitinib, Pazopanib
NCT01060488
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency
Growth Hormone Deficiency
P3
Completed69RCT, Open-label—
NCT00943722
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Cervical Cancers, Vulvar Cancer
P3
Completed3,074RCT, Open-labelV503
NCT00372060
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
Type 2 Diabetes Mellitus
P3
Completed134RCT, Double-blindsitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone, Comparator: placebo (unspecified)
NCT00474370
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
HIV Infections, Acquired Immunodeficiency Syndrome
P3
Completed400RCT, Double-blindVicriviroc, Placebo
NCT01860729
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)
Hypercholesterolemia
P3
Completed589RCT, Double-blindAnacetrapib, Placebo
NCT00535496
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
Neuromuscular Blockade
P3
Completed91RCT, Open-labelsugammadex
NCT01114425
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
HIV Infections
P3
Completed149Open-labelraltegravir (Isentress), Truvada®
NCT00092313
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)
Postoperative Pain
P3
Completed271RCT, Double-blindMK0966, rofecoxib, Comparator: oxycodone and acetaminophen
NCT01697592
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
Type 2 Diabetes Mellitus
P3
Completed585RCT, Double-blindOmarigliptin, Matching placebo to omarigliptin
NCT00092859
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
Obesity
P3
Completed1,500RCT, Double-blindMK0557
NCT00650689
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)
Hypercholesterolemia, Atherosclerosis
P3
Completed122RCT, Double-blindEzetimibe + Atorvastatin, Atorvastatin
NCT02819518
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Triple Negative Breast Cancer (TNBC)
P3
Completed882RCT, Double-blindPembrolizumab, Nab-paclitaxel, Paclitaxel, Gemcitabine, Carboplatin, Normale Saline Solution
NCT00269217
Lipid Efficacy Study (0524B-022)(COMPLETED)
Primary Hypercholesterolemia, Mixed Hyperlipidemia
P3
Completed1,400RCT, Double-blindniacin (+) laropiprant (+) simvastatin, Comparator: niacin (+) laropiprant, Comparator: simvastatin
NCT00473889
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
Stage IIIB or IV Non-Small Cell Lung Cancer
P2P3
Terminated253RCT, Double-blindvorinostat, Comparator: paclitaxel, Comparator: carboplatin, Comparator: placebo
NCT01977794
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Hypertension
P3
Completed200RCT, Open-labelBisoprolol/Amlodipine (Bisoprolol failed group), Bisoprolol/Amlodipine (Amlodipine failed group)
NCT02563002
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Colorectal Carcinoma
P3
Completed307RCT, Open-labelmFOLFOX6, FOLFIRI, Pembrolizumab, Bevacizumab, Cetuximab
NCT03884101
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Endometrial Neoplasms
P3
Completed842RCT, Open-labelLenvatinib, Pembrolizumab, Paclitaxel, Carboplatin
NCT01014013
Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)
Urinary Tract Infection
P3
Completed271RCT, Double-blindertapenem sodium (MK0826), Comparator: ceftriaxone sodium
NCT01033760
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
HIV-1 Infections
P3
Completed90RCT, Open-labelraltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine, darunavir; ritonavir; emtricitabine/tenofovir
NCT00092079
A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
Osteoporosis, Vitamin D Deficiency
P3
Completed652RCT, Double-blindMK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
NCT00283686
HALT Progression of Polycystic Kidney Disease Study A
Kidney, Polycystic
P3
Completed558RCT, Double-blindLisinopril, Telmisartan, Placebo
NCT00380367
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Papillomavirus Infections
P3
Completed110Open-labelQuadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
NCT02252016
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
Hepatitis C
P3
Completed159RCT, Double-blindGrazoprevir + Elbasvir, Placebo
NCT00092430
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
Measles, Mumps
P3
Completed1,200RCT, Double-blindV221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
NCT01590771
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
Type 2 Diabetes Mellitus
P3
Completed498RCT, Double-blindSitagliptin, Placebo, Gliclazide, Glimepiride, Metformin
NCT01340937
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
Bacterial Infections, Virus Diseases
P3
Completed2,808RCT, Double-blindV419, PENTACEL™, Prevnar 13™, RotaTeq™, Recombivax HB vaccine
NCT01047345
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
Cervical Cancers, Vulvar Cancers
P3
Completed924RCT, Double-blindV503, Placebo to V503
NCT03222167
Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
Chronic Hepatitis C Genotype 1B, Metabolic Syndrome
P3
Unknown60Open-labelElbasvir/ Grazoprevir 50/100 mg fixed dose combination
NCT03843632
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
Varicella
P3
Completed150Open-labelVARIVAX™
NCT02180165
Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Aspergillosis
P3
Completed116RCT, Open-labelPosaconazole, Voriconazole
NCT00681590
Safety of Vitamin D Supplementation in Older Persons
Vitamin D Deficiency
P3
Completed105RCT, Double-blind—
NCT00732641
Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
Multiple Myeloma
P3
Completed244RCT, Open-labelPeginterferon
NCT01293643
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
Vaginosis, Bacterial, Candidiasis, Vulvovaginal
P3
Completed99RCT, Open-label100 mg clindamycin /800 mg ketoconazole vaginal ovule, 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
NCT01462266
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
Type 2 Diabetes Mellitus
P3
Completed660RCT, Double-blindSitagliptin, Comparator: Placebo, Insulin Glargine, Metformin
NCT04384107
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)
Pneumococcal Infections
P3
Completed694RCT, Double-blindV114, PCV13
NCT00811928
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
Leukopenia
P3
Completed252RCT, Open-labelPosaconazole, Fluconazole
NCT02256436
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Urothelial Cancer
P3
Completed542RCT, Open-labelpembrolizumab, paclitaxel, vinflunine, docetaxel
NCT00521924
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
Rheumatoid Arthritis
P3
Terminated8RCT, Open-labelinfliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
NCT04233216
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
HIV-1 Infection
P3
Completed35RCT, Double-blindISL, DOR, DOR/ISL, Placebo to ISL, Placebo to DOR
NCT03537274
Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
Hepatitis C
P2P3
Completed1,224RCT, Double-blindPEG-Intron, Interferon Alfa-2B
NCT00210080
A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)
Lung Cancer
P3
Completed700RCT, Double-blindUridine 5'-Triphosphate (UTP) Solution for Inhalation
NCT00813709
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
Multiple Sclerosis, Clinically Isolated Syndrome
P3
Completed402RCT, Double-blindRNF, RNF, RNF, Placebo
NCT02660580
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Psoriasis, Plaque Type Psoriasis
P3
Completed443RCT, Double-blindMSB11022, Humira®
NCT00094770
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
Diabetes Mellitus, Type 2
P3
Completed1,172RCT, Double-blindsitagliptin (MK0431), Comparator: glipizide
NCT04767373
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Respiratory Syncytial Virus Infection
P2P3
Completed3,632RCT, Double-blindClesrovimab, Placebo
NCT00617123
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
Atherosclerosis, Ischemia
P3
Completed258RCT, Double-blindVorapaxar 2.5 mg, Placebo
NCT00131391
A Study of MK0364 in Obese Patients (0364-014)
Obesity
P3
Terminated2,400RCT, Double-blindComparator: taranabant, Comparator: placebo
NCT02282020
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
P3
Completed266RCT, Open-labelOLAPARIB, Single agent chemotherapy
NCT05191797
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
P1P2
Terminated3Open-labelBomedemstat, Atezolizumab
NCT01058642
Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia
Postherpetic Neuralgia
P2
Terminated41RCT, Double-blindADL5747, Placebo, Pregabalin
NCT01727336
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
P2
Terminated160RCT, Double-blindDalantercept and axitinib, Placebo and axitinib
NCT00652782
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
Congestive Heart Failure, Renal Impairment
P2
Completed160RCT, Double-blindrolofyline, Comparator Placebo (unspecified)
NCT01458392
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
P2
Completed46Open-labelDalantercept
NCT00097422
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
Diarrhea
P2
Completed—RCT, Open-labelOPT-80
NCT00358930
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
Head and Neck Neoplasms, Carcinoma, Squamous Cell
P2
Completed60Open-labelARQ 501
NCT04254978
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
Essential Thrombocythemia
P2
Completed73Open-labelBomedemstat
NCT01258569
Entereg Laparoscopic Colon Resection Study
Laparoscopic Colonic Resection
P2
Completed135RCT, Double-blindEntereg, Entereg, placebo
NCT03496207
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
P2
Completed106RCT, Double-blindPlacebo, Sotatercept
NCT00428844
Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
Osteomyelitis
P2
Completed75RCT, Open-labeldaptomycin, daptomycin, vancomycin, teicoplanin, nafcillin, oxacillin, flucloxacillin
NCT02733432
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
Candidiasis, Vulvovaginal, Mycoses
P2
Completed126RCT, Open-labelCD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
NCT04091360
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
COPD
P2
Completed40RCT, Double-blindPart A: RPL554, Placebos, Part B: RPL554
NCT02476890
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
Refractory Chronic Cough
P2
Completed36RCT, Double-blindGefapixant 100 mg, Placebo
NCT02842827
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
P1P2
Completed45Open-labelbomedemstat, tretinoin
NCT00622063
An Extension Study for Patients Previously Treated With ARQ 501
Cancer
P1P2
Completed1Open-labelARQ 501
NCT01749540
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
B-Thalassemia
P2
Completed64Open-labelluspatercept
NCT06854952
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
Overweight or Obesity
P2
Completed167RCT, Double-blindTERN-601
NCT03136185
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF)
P1P2
Completed90Open-labelBomedemstat
NCT02927080
Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral Muscular Dystrophy
P2
Terminated95RCT, Double-blindACE-083, ACE-083 or placebo
NCT00331045
Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid
Cancer, Constipation
P2
Terminated21RCT, Double-blindalvimopan, Placebo, Alvimopan 0.5 mg/day, Alvimopan 1 mg/day
NCT05558696
A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)
Polycythemia Vera
P2
Completed20Open-labelBomedemstat
NCT02397460
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
Refractory Chronic Cough
P2
Completed50RCT, Double-blindGefapixant, Placebo
NCT00816023
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
Bloodloss, Surgical Procedures, Operative
P2
Completed276RCT, Double-blindecallantide, placebo
NCT00310518
Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
Cancer
P2
Completed30Open-labelARQ 501
NCT00448864
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
Blood Loss, Surgical
P2
Terminated75RCT, Double-blindEcallantide, Placebo
NCT01275755
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Constipation
P2
Completed81RCT, Double-blindPlacebo, ADL5945 0.25 mg
NCT04945460
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Hypertension, Pulmonary
P2
Completed165RCT, Double-blindSotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
NCT00695903
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
Endocarditis, Bacterial, Infective Endocarditis
P2
Terminated38RCT, Double-blinddaptomycin, vancomycin
NCT02663622
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
P2
Completed44RCT, Double-blindEfprezimod alfa, Methotrexate, Tacrolimus, Placebo
NCT02349425
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
Refractory Chronic Cough
P2
Completed59RCT, Double-blindGefapixant, Placebo (for gefapixant)
NCT01569438
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
Bladder Pain Syndrome
P2
Terminated107RCT, Double-blindGefapixant, Placebo
NCT03443414
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD
P2
Completed405RCT, Double-blindRPL554 suspension, Placebo
NCT02609984
Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
Sarcoma, Myxoid/Round Cell Liposarcoma
P2
Terminated89RCT, Open-labelCMB305, atezolizumab
NCT02612610
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
Refractory Chronic Cough
P2
Completed253RCT, Double-blindGefapixant, Placebo (for gefapixant)
NCT02542254
The Effects of RPL554 on Top of Standard COPD Reliever Medications
Chronic Obstructive Pulmonary Disease
P2
Completed36RCT, Double-blindSalbutamol, Ipratropium, RPL554, Salbutamol matched placebo, Ipratropium matched placebo, RPL554 matched placebo
NCT05415722
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
P2
Completed162RCT, Double-blindTERN-501, TERN-101
NCT02502097
A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
Idiopathic Pulmonary Fibrosis, Cough
P2
Completed51RCT, Double-blindGefapixant
NCT04552704
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
Advanced Malignant Solid Neoplasm
P1P2
Terminated3RCT, Double-blindCD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration
NCT00507247
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
Staphylococcus Aureus
P2
Completed11Open-labelDaptomycin
NCT03342404
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
Thalassemia
P2
Completed145RCT, Double-blindLuspatercept
NCT01993329
A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)
Asthma
P2
Completed20RCT, Double-blindGefapixant 50 mg, Gefapixant 300 mg, Placebo to mimic 50 mg tablets, Placebo to mimic 300 mg tablets
NCT05013905
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Crohn Disease
P2
Completed55RCT, Open-labelTulisokibart
NCT02501473
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
Follicular Low Grade Non-Hodgkin's Lymphoma
P1P2
Terminated52RCT, Open-labelG100, Pembrolizumab, Rituximab
NCT03108066
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
VHL Gene Mutation, VHL
P2
Completed4Open-labelMK-3795
NCT02268409
Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
β-Thalassemia
P2
Completed51Open-labelluspatercept
NCT01178411
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
Advanced Solid Tumors
P1P2
Completed60Open-labelTivantinib, Anti-Cancer Combination Therapy
NCT00993863
Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction
Acute Pain
P2
Completed201RCT, Double-blindPlacebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg
NCT00761215
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Skin Diseases, Infectious, Skin Diseases, Bacterial
P2
Completed192RCT, Double-blindTR-701 200 mg, TR-701 300 mg, TR-701 400 mg
NCT03738150
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
P2
Completed21Open-labelSotatercept
NCT00467272
Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
P2
Completed30Open-labelDaptomycin
NCT00228592
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
Hepatitis B, Liver Transplantation
P2
Terminated—RCT, Open-labelHepeX-B, Hepatitis B Immune Globulin (HBIg)
NCT03577028
Study of HPN424 in Patients With Advanced Prostate Cancer
Advanced Prostate Cancer
P1P2
Terminated104Open-labelHPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target, HPN424 2 Prime Step IV 300 ng/kg Target, HPN424 2 Prime Step IV 450 ng/kg Target, HPN424 Fixed SC
NCT07132983
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
P2
Completed33RCT, Double-blindEnsifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation)
NCT03216499
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
P2
Completed24Open-labelHIF-2alpha Inhibitor PT2385
NCT02477709
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
P2
Completed6Open-labelGefapixant
NCT01070290
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
Gastric Cancer
P2
Withdrawn—RCT, Open-labelARQ 197, Oxaliplatin, capecitabine or irinotecan
NCT01554579
A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee
Osteoarthritis of the Knee
P2
Completed171RCT, Double-blindGefapixant, Sugar Pill
NCT02303782
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Acute Myeloid Leukemia
P1P2
Withdrawn—RCT, Open-labelOTX015, Vidaza (azacitidine)
NCT03673670
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
COPD
P2
Completed79RCT, Double-blindRPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
NCT02612623
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Refractory Chronic Cough
P2
Completed24RCT, Double-blindGefapixant, Placebo (for gefapixant)
NCT03094832
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
P1P2
Terminated50Open-labelMiransertib
NCT00426933
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
Soft Tissue Infections
P2
Completed100RCT, Open-labelDaptomycin, Vancomycin
NCT00159614
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Heart Failure, Congestive, Renal Insufficiency
P2
Completed30RCT, Double-blindKW-3902IV
NCT01749514
Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
Anemia
P2
Completed116Open-labelLuspatercept
NCT01752920
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Solid Tumor
P1P2
Completed119Open-labelDerazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
NCT00159627
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
Heart Failure, Congestive
P2
Completed52RCT, Double-blindKW-3902IV
NCT02406781
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Sarcoma
P2
Completed129Open-labelCombination of MK3475 with Metronomic CP, Combination of MK3475 with Metronomic CP and G100
NCT02919995
A Study of RPL554 in Patients With Cystic Fibrosis
Cystic Fibrosis
P2
Completed10RCT, Double-blindRPL554, Placebo
NCT00557609
Phase 2 Study in Patients With MiT Tumors
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS)
P2
Completed47Open-labelARQ 197
NCT06609460
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Influenza
P2
Completed5,071RCT, Double-blind—
NCT05569538
Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis
Myelofibrosis
P2
Unknown40Open-labelBomedemstat
NCT00101998
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
Constipation, Bowel Dysfunction
P2
Completed233RCT, Double-blindalvimopan, placebo
NCT07016412
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)
Chronic Obstructive Pulmonary Disease
P2
Completed497RCT, Double-blindEnsifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
NCT06545500
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Chronic Obstructive Pulmonary Disease
P2
Completed46RCT, Double-blindGlycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo
NCT04527471
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
Coronavirus Infection, Covid-19
P2
Completed45RCT, Double-blindEnsifentrine Dose 1, Placebo pMDI
NCT01147640
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
Complicated Intra-abdominal Infection
P2
Completed122RCT, Double-blindCXA-101/ tazobactam and metronidazole, meropenem plus saline placebo
NCT05523089
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Influenza
P2
Completed59RCT, Double-blindSaline placebo
NCT00888940
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Bloodloss, Surgical Procedures, Operative
P2
Completed243RCT, Double-blindEcallantide, Cyklokapron(R)
NCT02427165
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
Asthma
P2
Completed29RCT, Double-blindRPL554, Salbutamol, Placebo
NCT01146574
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Anemia
P2
Completed50RCT, Single-blindSotatercept, Placebo
NCT00135577
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Cancer, Bowel Dysfunction
P2
Completed67Double-blindalvimopan, placebo
NCT01395758
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
P2
Completed96RCT, Open-labelARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine
NCT03124459
Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease
P2
Terminated63RCT, Double-blindACE-083, Placebo
NCT01591863
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Clostridium Difficile-associated Diarrhea
P2
Completed38Open-labelfidaxomicin
NCT00603265
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Peripheral Neuropathy, Neuropathic Pain
P2
Completed226RCT, Double-blindADL5859, Duloxetine, Placebo
NCT03028142
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
Chronic Obstructive Pulmonary Disease Moderate
P2
Completed30RCT, Double-blind1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium, Placebo plus tiotropium
NCT00558207
A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Neoplasms
P2
Completed43RCT, Open-labelARQ 197, gemcitabine
NCT00988741
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Unresectable Hepatocellular Carcinoma
P2
Completed107RCT, Double-blindARQ 197, Placebo
NCT01519778
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Major Cutaneous Abscess, Cellulitis
P2
Completed200Open-labelTR701 FA
NCT01432730
A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
Chronic Cough
P2
Completed24RCT, Double-blindGefapixant, Placebo
NCT04996797
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Ulcerative Colitis
P2
Completed178RCT, Double-blindTulisokibart
NCT03943290
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease
P2
Terminated62RCT, Open-labelACE-083
NCT04060407
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Metastatic Melanoma
P1P2
Withdrawn—Open-labelCD24Fc, Ipilimumab, Nivolumab
NCT04504916
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer
P2
Terminated102Open-labelZilovertamab vedotin
NCT01085591
Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection, Diarrhea
P2
Completed210RCT, Double-blindCB-183,315, Placebo, Vancomycin
NCT01099761
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
P2
Terminated24RCT, Double-blindACE-031 0.5 mg/kg q4wk, ACE-031 1.0 mg/kg q2wk
NCT04328077
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
NASH - Nonalcoholic Steatohepatitis
P2
Completed101RCT, Double-blindTERN-101
NCT00921024
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Complicated Urinary Tract Infection
P2
Completed129RCT, Double-blindCXA-101, Ceftazidime
NCT03960541
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
HIV Infections, Dyslipidemias
P2
Terminated8RCT, Double-blindEfprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
NCT01239758
Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
P2
Terminated11Open-labelACE-031 (Extension of cohort 1 from core study, A031-03), ACE-031 (Extension of cohort 2 from core study, A031-03), ACE-031 (Extension of cohort 3 from core study, A031-03)
NCT04027439
Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler
Pulmonary Disease, Chronic Obstructive
P2
Completed37RCT, Double-blindPart A: RPL554, Part B: RPL554, Placebos
NCT00979953
Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee
Osteoarthritis of the Knee
P2
Completed408RCT, Double-blindADL5859, ADL5747, Oxycodone CR, Placebo
NCT02268383
Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)
Myelodysplastic Syndromes
P2
Completed75Open-labelLuspatercept
NCT05223920
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
Thrombocythemia, Essential, Primary Myelofibrosis
P2
Completed81Open-labelBomedemstat
NCT00102700
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
Pancreatic Cancer, Adenocarcinoma
P2
Completed66Open-labelARQ 501 in combination with gemcitabine
NCT02734862
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
Candidemia, Mycoses
P2
Completed207RCT, Double-blindCD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
NCT01207427
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Opioid Induced Constipation
P2
Completed131RCT, Double-blindPlacebo, ADL5945 0.1 mg, ADL5945 0.25 mg
NCT02024087
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
P1P2
Completed21Open-labelDalantercept plus sorafenib
NCT00777309
A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
P2
Completed167RCT, Double-blindARQ 197, Erlotinib, Placebo
NCT02296476
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
Glioblastoma Multiforme
P2
Terminated12Open-labelBirabresib
NCT03937479
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
COPD
P2
Completed416RCT, Double-blindEnsifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
NCT00626275
Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Completed46RCT, Double-blindADL5859, Naproxen, Placebo, ADL5859, Placebo
NCT00732810
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
P2
Completed97RCT, Open-labelSCH 727965, Capecitabine, Erlotinib
NCT01564459
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
Diabetic Neuropathy, Painful
P2
Completed170RCT, Double-blindMK-6096, Placebo
NCT01527383
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
Herpes Zoster
P2
Completed354RCT, Double-blindV212, Placebo
NCT05258279
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation
P2
Completed30Open-labelPembrolizumab, Lenvatinib, Carboplatin, Pemetrexed
NCT03887442
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Head and Neck Cancer
P2
Terminated17RCT, Open-labelPaclitaxel, Cetuximab + Paclitaxel
NCT03012620
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Sarcoma, Ovarian Neoplasm
P2
Completed334Open-labelPembrolizumab
NCT04209686
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Advanced Gastric Adenocarcinoma
P2
Completed19Open-labelPaclitaxel, Olaparib, Pembrolizumab
NCT00787527
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Lymphoma
P1P2
Completed14Open-labelZolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
NCT07876128
A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)
Advanced Solid Tumors, Malignant Neoplasm
P1P2
Not Yet Recruiting300RCT, Open-labelMK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist, Corticosteroid, Steroid mouthwash (dexamethasone or equivalent)
NCT03547583
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
Chronic Heart Failure With Preserved Ejection Fraction
P2
Completed789RCT, Double-blindVericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo
NCT01735422
A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women
Infertility
P2
Completed67RCT, Open-labelr-hFSH, r-hLH, u-hCG
NCT03139851
Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Metastatic Breast Cancer
P2
Completed36Open-labelCyclophosphamide 50mg, Pembrolizumab 100 MG in 4 ML Injection
NCT03407170
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
Advanced Melanoma
P2
Terminated1Open-labelpembrolizumab
NCT00260039
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
HPV, Cervical Cancer
P2
Completed680RCT, Double-blindComparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2, Comparator: octavalent HPV Vaccine - dose formulation 3
NCT00638963
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
Breast Neoplasm, Brain Neoplasm
P2
Terminated6RCT, Open-labeltemozolomide
NCT01717287
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
HIV Infection
P2
Completed32Open-labelRaltegravir Film-coated Tablet, Raltegravir Chewable Tablet, Other Anti-Retroviral Therapy
NCT00103714
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
Cystic Fibrosis
P2
Completed72RCT, Double-blinddenufosol tetrasodium (INS37217)
NCT01523639
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Colorectal Cancer, Steatohepatitis
P2
Terminated8RCT, Double-blindMetformin/Placebo
NCT03631407
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Colorectal Neoplasms
P2
Completed41RCT, Open-labelVicriviroc, Pembrolizumab
NCT01432574
Study of Gardasil in Mid-Adult Males (MAM)
Human Papillomavirus
P2
Completed150Open-labelGardasil
NCT05061420
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Squamous Cell Carcinoma of Head and Neck
P2
Terminated59Open-labelPembrolizumab, SAR444245 (Thor-707), Cetuximab
NCT02964559
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
P2
Completed11Open-labelPembrolizumab
NCT03278405
Avelumab in G3 NEC
Neuroendocrine Carcinoma
P1P2
Completed10Open-labelAvelumab
NCT03693170
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
BRAF V600E-mutant Metastatic Colorectal Cancer
P2
Completed95Open-labelencorafenib, Binimetinib, Cetuximab
NCT05255666
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Triple Negative Breast Cancer, Brain Metastases
P2
Withdrawn—Open-labelPembrolizumab, Liposomal Irinotecan
NCT05617313
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer, Metastatic NSCLC
P2
Terminated21Open-labelPembrolizumab, GT103
NCT01096667
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
Diabetes Mellitus, Type 2, Hypertension
P2
Completed194RCT, Double-blindPlacebo to Ertuglilflozin 1 or 5 mg, Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg, HCTZ 12.5mg, Placebo to HCTZ, Placebo to ertuglilflozin 25 mg
NCT02987972
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
Pneumococcal Infections
P2
Completed1,051RCT, Double-blindV114 Lot 1, V114 Lot 2, Prevnar 13™
NCT00127192
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
Type 2 Diabetes Mellitus
P2
Completed363RCT, Double-blindsitagliptin phosphate, Comparator: placebo (unspecified)
NCT00243230
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
HIV Infections
P2
Completed116RCT, Double-blindVicriviroc 30 mg, Vicriviroc 20 mg, Placebo, Placebo, Background ART Regimen
NCT02097108
Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
HIV Infections
P2
Completed11Open-labelRaltegravir
NCT02335424
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
Urothelial Cancer
P2
Completed374Open-labelpembrolizumab
NCT02178722
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
P1P2
Completed444Open-labelMK-3475, INCB024360
NCT03245151
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Recurrent and Refractory Solid Tumors
P1P2
Completed64Open-labelLenvatinib, Everolimus
NCT03322566
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Lung Cancer
P2
Completed233RCT, Double-blindPembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo
NCT03812796
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
Cancer, GI Cancer
P2
Unknown75Open-labelDomatinostat, Avelumab
NCT00894569
Paclitaxel/Carboplatin With or Without Cetuximab in CUP
Neoplasms, Unknown Primary, Carcinoma
P2
Unknown150RCT, Open-labelpaclitaxel/carboplatin, cetuximab
NCT00831545
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
Metastases of Central Nervous System, Melanoma
P2
Completed162Open-labelTemozolomide
NCT03477175
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Solid Tumors
P2
Completed40Open-labelE7080, Comparator Drug, Comparator Drug: Sorafenib
NCT00968617
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)
Anemia, Chronic Kidney Disease
P2
Terminated7RCT, Open-labelMK2578, MK2578, MK2578, Comparator: darbepoetin alfa
NCT00475735
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
Attention-Deficit/Hyperactivity Disorder (ADHD)
P2
Completed72RCT, Double-blindMK0249, Concerta (methylphenidate), Placebo
NCT00551018
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
HIV Infections
P2
Completed218RCT, Open-labelVicriviroc, emtricitabine and tenofovir disoproxil fumarate
NCT02688608
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
P2
Completed6Open-labelPembrolizumab
NCT03506997
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Castration-resistant Prostate Cancer
P2
Unknown100Open-labelPembrolizumab
NCT01165320
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
Candidiasis, Esophageal, Candidiasis, Invasive
P2
Completed20Open-labelCaspofungin
NCT00362024
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
Alzheimer's Disease
P2
Terminated24RCT, Double-blindMK0952, Comparator: Placebo
NCT01758588
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Myelofibrosis
P2
Terminated8RCT, Open-labelPeginterferon alfa-2a
NCT00988728
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
Schizophrenia
P2
Withdrawn—RCT, Double-blindSCH 900435 (Org 25935), Placebo, Olanzapine
NCT01720875
Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)
Multiple Myeloma
P2
Completed16Open-labelVorinostat Velcade Dexamethasone
NCT01059825
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
Diabetes Mellitus, Type 2
P2
Completed375RCT, Double-blindPlacebo to Ertugliflozin, Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg, Sitagliptin 100 mg, Placebo to Sitagliptin, Metformin
NCT00424424
A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)
Pain, Postoperative
P2
Terminated81RCT, Double-blindMK0719
NCT00439517
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
Previously Untreated Metastatic Colorectal Cancer
P2
Completed302RCT, Open-labelUFOX + Cetuximab, FOLFOX4 + Cetuximab
NCT05156268
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Endometrial Carcinosarcoma
P2
Completed26Open-labelPembrolizumab, Olaparib
NCT02549209
Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer, Endometrial Adenocarcinoma
P2
Completed46Open-labelPembrolizumab, Paclitaxel, Carboplatin
NCT01513551
The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)
Pneumococcal Infections
P2
Completed692RCT, Double-blindPneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13®
NCT02573181
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
Pneumococcal Infections
P2
Completed253RCT, Double-blindV114, Prevnar 13™
NCT03217136
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
Complicated Intra-Abdominal Infection
P2
Completed94RCT, Double-blindCeftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole
NCT01066871
Sprifermin (AS902330) in Cartilage Injury Repair (CIR)
Isolated Cartilage Injury of the Knee
P2
Terminated74RCT, Double-blindSprifermin (AS902330) 10 mcg, Sprifermin (AS902330) 30 mcg, Sprifermin (AS902330) 100 mcg
NCT00504530
r-hLIF for Improving Embryo Implantation in IVF
Infertility Implantation Failure
P1P2
Completed50RCT, Double-blindEmfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
NCT03160079
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
B-Cell Acute Lymphoblastic Leukemia, Adult
P1P2
Completed16Open-labelblinatumomab, pembrolizumab
NCT03664024
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Non-Small Cell Lung Cancer
P2
Completed118Open-labelPembrolizumab, Pemetrexed, Carboplatin, Cisplatin
NCT02212379
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
HIV-1 Infection
P2
Completed170Open-labelraltegravir and etravirine
NCT04914897
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Pleural Mesothelioma, Non-small Cell Lung Cancer
P2
Terminated106Open-labelTHOR-707, Pembrolizumab
NCT02705820
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
Metastatic Non Small Cell Lung Cancer
P2
Completed48Open-labelPembrolizumab
NCT01492582
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
Cancer Survivor, Prevention of Human Papillomavirus Infection
P2
Completed1,499Open-labelquadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
NCT04807816
Targeting ATR in Soft-tissue Sarcomas
Leiomyosarcoma, Adult
P2
Completed58RCT, Open-labelAssociation of berzosertib with gemcitabine, Gemcitabine
NCT00551187
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Cervical Cancer, Vulvar Cancer
P2
Completed620RCT, Double-blindV504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo (unspecified)
NCT00553514
AS900672-Enriched in Ovulation Induction
Ovulation Induction
P2
Terminated71RCT, Single-blindAS900672-Enriched 10 microgram (mcg), AS900672-Enriched 20 mcg, AS900672-Enriched 30 mcg, AS900672-Enriched 40 mcg, Follitropin alfa 75 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
NCT00704184
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
Hepatitis C
P2
Completed95RCT, Double-blindComparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin, Comparator: placebo
NCT02490436
Novel Treatment Option for Neuropathic Pain
Neuralgia, Complex Regional Pain Syndromes
P2
Completed15RCT, Double-blindCetuximab, Placebo
NCT00503971
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Non-small Cell Lung Cancer
P1P2
Terminated33Open-labelVorinostat plus Erlotinib
NCT03818893
Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII
Advanced Melanoma
P2
Unknown46Open-labelCombination of GEN0101 and Pembrolizmub
NCT00330395
Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)
Candidiasis
P2
Completed16Open-labelcaspofungin acetate
NCT00729222
Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)
Heart Failure
P2
Completed60RCT, Double-blindComparator: Placebo, rolofylline
NCT04158700
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Advanced Cancer
P1P2
Withdrawn—Open-labelLY3200882, Pembrolizumab
NCT00506987
Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)
Cough
P2
Completed31RCT, Double-blindSCH 486757, Placebo Dose 1
NCT00282763
A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)
Neuralgia, Postherpetic
P2
Terminated12RCT, Double-blindMK0686
NCT00505752
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Infertility
P2
Completed520RCT, Single-blindAS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
NCT02039674
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
Non-small Cell Lung Carcinoma
P1P2
Completed267RCT, Open-labelPembrolizumab, Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed, Ipilimumab, Erlotinib, Gefitinib
NCT00572910
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
Staphylococcus Aureus Infection
P2
Completed206RCT, Double-blindComparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO)
NCT00120835
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
Chronic Hepatitis C
P1P2
Completed—RCT, Open-labelvalopicitabine, pegylated interferon
NCT00539578
Treatment of Patients With Anxiety Disorder (0777-022)
Generalized Anxiety Disorder
P2
Completed270RCT, Double-blindMK0777, Comparator: placebo (unspecified)
NCT00880763
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
Hepatitis C
P2
Completed90RCT, Double-blindVaniprevir, Pegylated Interferon (peg-IFN), Ribavirin, Comparator: Placebo
NCT03242915
Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
Non-small Cell Lung Cancer
P2
Completed33Open-labelPembrolizumab, Carboplatin, Pemetrexed
NCT00600691
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy
Hematuria, Hematospermia
P2
Terminated29RCT, Double-blindFinasteride
NCT01181622
A Safety and Tolerability Study of Denufosol in 2-4 Year Olds
Cystic Fibrosis
P2
Completed25RCT, Double-blinddenufosol tetrasodium Inhalation Solution, 0.9% w/v sodium chloride solution
NCT01057511
Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration
Postmenopausal Endometrium
P1P2
Completed51RCT, Single-blindCrinone 8%, Progesterone
NCT01094548
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Multiple Myeloma
P2
Completed34RCT, Open-labelTecemotide (L-BLP25), Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
NCT00325455
MK0859 Dose-Ranging Study (0859-003)
Hypercholesterolemia, Mixed Hyperlipemia
P2
Terminated500RCT, Double-blindMK0859
NCT02348008
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Clear Cell Renal Carcinoma
P1P2
Completed61Open-labelMK-3475, Bevacizumab, MK-3475, Bevacizumab
NCT02677155
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Follicular Lymphoma
P2
Completed10Open-labelRituximab, Autologous dendritic cells, GM-CSF, Pembrolizumab
NCT02500121
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Urothelial Carcinoma, Bladder Cancer
P2
Completed108RCT, Double-blindPembrolizumab
NCT00533676
Endpoint Validation Study (0524A-015)
Flushing
P2
Completed165RCT, Double-blindMK0524A, /Duration of Treatment : 8 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks
NCT03322540
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Lung Cancer
P2
Completed154RCT, Double-blindPembrolizumab, Epacadostat, Placebo
NCT00574587
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Breast Cancer
P1P2
Completed55Open-labelVorinostat, Paclitaxel, Trastuzumab, Doxorubicin, Cyclophosphamide
NCT04564547
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
HIV-1 Infection
P2
Completed161RCT, Double-blindIslatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF
NCT04624243
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Schizophrenia
P2
Completed499RCT, Double-blindElpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
NCT00002225
A Study of Efavirenz in Combination With Stavudine and Didanosine
HIV Infections
P2
Completed60—Efavirenz, Stavudine, Didanosine
NCT06805864
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
P2
Not Yet Recruiting45Open-labelPembrolizumab (KEYTRUDA®)
NCT00508664
Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)
Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma
P2
Completed180RCT, Open-labelCetuximab, Docetaxel, Cisplatin (TP), 5-Fluorouracil (TPF) (only until Feb 2009)
NCT00807443
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
HIV-1, HIV Infections
P2
Completed10Open-labelRaltegravir
NCT07716917
Genitourinary Tumors With Sacituzumab Tirumotecan
Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
P2
Not Yet Recruiting100Open-labelSacituzumab Tirumotecan (SKB264)
NCT00725725
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
Panic Disorder
P2
Terminated46RCT, Double-blindOrg 25935, Org 25935, Placebo
NCT00836927
Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
Advanced Cancers
P2
Terminated7Open-labelRidaforolimus Tablet, Ridaforolimus Intravenous (IV) Infusion
NCT04224740
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
Penile Carcinoma
P2
Completed37Open-labelPembrolizumab, Standard of care therapy
NCT04489940
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Triple Negative Breast Neoplasms
P2
Terminated11Open-labelBintrafusp alfa
NCT02116660
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
HIV Infections
P2
Terminated11RCT, Open-labelRaltegravir (MK-0518), Nevirapine, Lamivudine, Tenofovir, Emtricitabine, Lopinavir, Ritonavir, Atazanavir, Darunavir
NCT02982720
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Advanced Cholangiocarcinoma
P2
Terminated4Open-labelPembrolizumab, Sylatron
NCT00971932
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Squamous Cell Carcinoma of the Head and Neck
P2
Completed33Open-labelCetuximab, Cisplatin/Carboplatin, 5-Fluorouracil
NCT00642993
Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)
Obesity, Overweight
P2
Completed401RCT, Double-blindSCH 497079, Placebo
NCT02054442
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
P1P2
Unknown52RCT, Open-labelCetuximab, Methotrexate
NCT04003103
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
HIV-1 Infection
P2
Completed242RCT, Double-blindIslatravir, Placebo
NCT00798213
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute
P2
Terminated29RCT, Open-labelSCH 727965, Gemtuzumab ozogamicin
NCT03598608
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Hodgkin Disease, Lymphoma, Non-Hodgkin
P1P2
Terminated137Open-labelpembrolizumab, Favezelimab
NCT02122861
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed
P1
Completed47Open-labelID-LV305
NCT01442831
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
Healthy
P1
Completed6Open-labelHuman ADME
NCT00658554
Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers
Healthy
P1
Completed24RCT, Open-labelARQ 197
NCT05285137
Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
Healthy
P1
Completed77RCT, Double-blindSaline placebo
NCT00679835
PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections
Gram Positive Infection, Concurrent Antibiotic Treatment
P1
Completed24Open-labeldaptomycin
NCT01461460
A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects
Healthy Volunteer
P1
Completed48RCT, Double-blindTR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
NCT01225536
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Solid Tumor
P1
Completed24Open-labelARQ 736
NCT00671359
Food Effects of Single Oral Dose of 600mg TR-701
Healthy
P1
Completed12RCT, Open-labelTR-701 600mg
NCT01577459
A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response
Healthy Subjects
P1
Completed18RCT, Double-blindTR-701 FA with PSE
NCT03478319
A Study of ACE-2494 in Healthy Subjects
Healthy Volunteers
P1
Completed48RCT, Double-blindACE-2494 or placebo
NCT02387125
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Sarcoma, Melanoma
P1
Terminated79Open-labelCMB305, G100, Metronomic CPA
NCT01724320
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
Solid Tumors
P1
Unknown20Open-labelOTX008
NCT00524524
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed9Open-labelARQ 501
NCT00651638
A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype
Healthy
P1
Completed17Open-labelTreatment with ARQ 197
NCT00612703
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Cancer
P1
Completed32Open-labelARQ 197
NCT01019395
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Gram Positive Bacterial Infection
P1
Completed23Open-labelDaptomycin
NCT01713582
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma
P1
Completed141Open-labelOTX015/Birabresib
NCT00075933
ARQ 501 in Subjects With Cancer
Cancer
P1
Completed80Open-labelARQ 501
NCT05603182
A Study of PRA052 in Healthy Volunteers
Healthy
P1
Completed96RCT, Double-blindPRA052
NCT02492776
A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
Healthy
P1
Completed14Open-labelOmeprazole, Gefapixant, Gefapixant
NCT00876655
Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate
Healthy
P1
Completed12RCT, Open-labelTR-701 di-sodium phosphate salt, TR-701 free acid phosphate
NCT04222985
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
Genital Herpes
P1
Terminated24RCT, Double-blindHSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3, HSV 2 Formulation 4, HSV 2 Formulation 5, HSV 2 Formulation 6, Sodium Chloride 0.9%
NCT00755638
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
Muscle Loss
P1
Completed48RCT, Double-blindACE-031
NCT03872206
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
Advanced Cancers Associated With Mesothelin Expression
P1
Completed95Open-labelHPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target, 2 Prime Step IV 900-14000 ng/kg Target
NCT00490737
Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)
End-Stage Renal Disease
P1
Completed12Open-labeldaptomycin
NCT02229877
A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)
Healthy Volunteers
P1
Completed18Single-blindOmeprazole, Gefapixant, Gefapixant, Gefapixant
NCT01452828
A Pharmacokinetics and Safety Study in Subjects With Renal Impairment
Renal Impairment
P1
Completed24Open-labelTR-701 FA single infusion, TR-701 FA, TR-701 FA
NCT00671814
Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults
Healthy Subjects
P1
Completed80RCT, Double-blindTR-701, linezolid, placebo
NCT07838987
A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
Healthy
P1
Completed196RCT, Open-labelEmbibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
NCT00983255
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
Bacterial Infections
P1
Completed90RCT, Double-blindTR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
NCT00874042
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed74Open-labelTreatment with ARQ 197 in combination with gemcitabine
NCT02553356
PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers
Healthy
P1
Completed16RCT, Open-labelPT2385
NCT00882557
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
P1
Completed16RCT, Open-labeldaptomycin, daptomycin
NCT01502800
Clinical Trial of ARQ 761 in Advanced Solid Tumors
Solid Tumors
P1
Completed91RCT, Open-labelARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest
NCT00136292
Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics
Gram-positive Bacterial Infections
P1
Completed33Open-labeldaptomycin
NCT01397604
The Effects of GLA on Human Volunteers
Healthy Volunteers
P1
Completed32RCT, Double-blindGLA-AF, GLA-SE
NCT02259114
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
NUT Midline Carcinoma, Triple Negative Breast Cancer
P1
Completed47Open-labelBirabresib
NCT02551549
An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects
Healthy
P1
Completed24RCT, Double-blindCD101 IV, Placebo
NCT02015416
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Melanoma, Ovarian Cancer
P1
Completed13Open-labelIDC-G305
NCT00302172
ARQ 197 in Subjects With Metastatic Solid Tumors
Cancer, Tumor
P1
Completed78Open-labelARQ 197
NCT01623401
A Phase 1, Open-Label, 10 Day Safety Study
Healthy Subjects
P1
Completed72Open-labelTR-701 FA
NCT01539473
A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge
Healthy Volunteers
P1
Completed30RCT, Double-blindTR-701 FA with Tyramine, Placebo-controlled withTyramine
NCT00825487
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
P1
Completed50Open-labelARQ 621
NCT00612209
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Cancer, Advanced Solid Tumors
P1
Completed51Open-labelARQ 197
NCT04948554
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
Systemic Sclerosis With and Without Interstitial Lung Disease
P1
Terminated5RCT, Double-blindMK-2225, Placebo
NCT00666601
Microdialysis and Pharmacokinetic Study of TR-701
Healthy
P1
Completed15Open-labelTR-700 (active moiety), TR-701 (pro-drug)
NCT02083627
A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects
Drug-Drug Interaction (DDI), Intestinal Absorption
P1
Completed25RCT, Open-labelrosuvastatin, fidaxomicin
NCT00709540
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
Osteoporosis
P1
Completed40RCT, Double-blindACE-011 or placebo
NCT03445169
A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets
Healthy
P1
Completed16RCT, Open-labelBelzutifan
NCT02035657
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Merkel Cell Carcinoma
P1
Completed10Open-labelGLA-SE
NCT00099190
ARQ 501 in Combination With Docetaxel in Patients With Cancer
Carcinoma
P1
Completed50Open-labelARQ 501
NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
P1
Completed91Open-labelZilovertamab vedotin
NCT02790840
A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations
Healthy
P1
Completed32Open-labelOmeprazole, Omeprazole, Gefapixant, Gefapixant
NCT04897594
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
P1
Completed52RCT, Double-blindTERN-201
NCT02508740
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
Renal Impairment
P1
Terminated31RCT, Open-labelbevenopran
NCT02508753
Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects
Healthy
P1
Completed52RCT, Double-blindCXA-101/tazobactam, CXA-101/tazobactam, Moxifloxacin, placebo
NCT01473095
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Solid Tumor, Malignant Lymphoma
P1
Completed120Open-labelARQ 092
NCT02761694
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
Cancer, Solid Tumors
P1
Terminated78Open-labelVevorisertib, Fulvestrant, Paclitaxel
NCT01271998
Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
Bacterial Infection
P1
Completed20Open-labelTR-701 FA
NCT02652936
A Pharmacokinetics Study of AF-130 in Healthy Subjects
Healthy Volunteers
P1
Completed80RCT, Double-blindAF-130, Placebo comparator
NCT05619536
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Healthy
P1
Completed28RCT, Double-blindSaline placebo
NCT00802555
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
Cirrhosis, Hepatocellular Carcinoma
P1
Completed21Open-labelARQ 197
NCT02387372
Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
Critically Ill, Pneumonia
P1
Completed37Open-labelCeftolozane/Tazobactam - Multiple Doses, Ceftolozane/Tazobactam - Single Dose
NCT04676178
A Study of PRA023 in Healthy Volunteers
Healthy
P1
Completed69RCT, Double-blindPRA023
NCT01431833
A PK and Safety Study in Subjects With Hepatic Impairment
Hepatic Impairment
P1
Completed32Open-labelTR-701 FA
NCT00827177
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed87Open-labelTreatment with ARQ 197 in combination with sorafenib
NCT00398840
A Study of ARQ 171 in Patients With Advanced Solid Tumors
Cancer
P1
Terminated14Open-labelARQ 171
NCT02307162
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder
P1
Completed112RCT, Double-blindRPL554, Placebo
NCT01496677
Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects
Healthy Subjects
P1
Completed28RCT, Open-labelTR-701 FA 200 mg, TR-701 FA 200 mg
NCT00996957
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Advanced Solid Tumors, Multiple Myeloma
P1
Completed37Open-labelACE-041
NCT02650895
Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
Healthy Volunteers
P1
Completed40RCT, Double-blindEfprezimod alfa, Saline
NCT03006887
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Solid Tumors
P1
Completed6Open-labellenvatinib, pembrolizumab
NCT02516904
A Single Ascending Dose Study of CD101 IV in Healthy Subjects
Healthy
P1
Completed32RCT, Double-blindCD101 IV, Placebo
NCT02266706
Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis
P1
Completed43Open-labelCeftolozane/Tazobactam 1000/500 mg, Ceftolozane/Tazobactam 30/15 mg/kg, Ceftolozane/Tazobactam 20/10 mg/kg, Ceftolozane/Tazobactam 18/9 mg/kg, Ceftolozane/Tazobactam 12/6 mg/kg
NCT07839000
A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)
Healthy
P1
Completed8Open-labelTERN-701
NCT01432717
Study of ACE-536 in Healthy Postmenopausal Women
Anemia
P1
Completed40RCT, Double-blindACE-536
NCT01156077
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
Bacterial Infection
P1
Completed20Open-labelTR-701 FA, TR-701 FA
NCT02257489
Phase 1 Study of ACE-083 in Healthy Subjects
Musculoskeletal Diseases
P1
Completed58RCT, Double-blindACE-083
NCT05354349
Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023
Healthy
P1
Completed49RCT, Double-blindPRA023 IV Low Dose, PRA023 SC, Placebo IV, Placebo SC, PRA023 IV High Dose
NCT03006926
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Hepatocellular Carcinoma
P1
Completed104Open-labellenvatinib, pembrolizumab (200 mg)
NCT01813448
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects
Pharmacokinetics of Fidaxomicin, Healthy Subjects
P1
Completed36RCT, Double-blindFidaxomicin, Placebo
NCT02476955
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
Solid Tumors, Ovarian Cancer
P1
Terminated41Open-labelARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
NCT02341599
Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)
Healthy Volunteers, Renal Impairment
P1
Completed40Open-labelMK-6183
NCT00952887
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
Muscular Atrophy
P1
Completed70RCT, Double-blindACE-031, Placebo
NCT01149720
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Solid Tumors
P1
Completed24RCT, Open-labelTivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral
NCT01919125
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
Hepatitis C, Chronic
P1
Completed36Open-labelIDX719
NCT01050283
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
Advanced Pancreatic Adenocarcinoma
P1
Terminated15Open-label—
NCT02269423
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
Ebola Virus
P1
Completed39RCT, Double-blindV920
NCT03326986
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)
Pharmacokinetics, Cancer
P1
Completed24RCT, Double-blindMK-7252, Placebo
NCT04880213
Study of M5049 in Healthy Japanese and Caucasian Participants
Healthy
P1
Completed36Open-labelM5049, M5049, M5049
NCT00694083
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
Neoplasm
P1
Completed13Open-labelRidaforolimus
NCT00632931
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
Advanced Cancer Relapsed, Advanced Cancer Refractory
P1
Completed25RCT, Single-blindvorinostat, Comparator: placebo (unspecified)
NCT01032681
EMD 521873 in Advanced Solid Tumors, MTD Finding
Non-Hodgkin Lymphoma
P1
Completed66Open-labelEMD 521873, EMD 521873, EMD 521873
NCT04374877
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
P1
Completed145Open-labelCHS-388, Pembrolizumab, Toripalimab
NCT03340766
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
P1
Completed31Open-labelBlinatumomab, Pembrolizumab
NCT02512172
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Colorectal Cancer
P1
Completed27RCT, Double-blindOral CC-486, Romidepsin, MK-3475
NCT03188523
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
HIV-1 Infection
P1
Completed12Open-labelMK-8504
NCT00902161
A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)
Type 2 Diabetes Mellitus
P1
Completed22RCT, Double-blindMK0893, MK0893-matched Placebo, Propranolol Hydrochloride (HCL)
NCT06942741
A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)
Healthy
P1
Completed52RCT, Open-labelCalderasib OCT, Calderasib FCT
NCT01676753
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer
P1
Completed32Open-labelDinaciclib, Pembrolizumab
NCT01731587
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) Stage III
P1
Withdrawn—Open-labelCyclophosphamide (CPA)
NCT01385566
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
Herpes Zoster
P1
Completed223RCT, Single-blindZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous, ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous, ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal, ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal, Full Dose Intradermal Placebo, Intradermal Placebo
NCT01023737
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
Malignant Solid Tumour
P1
Completed72Open-labelHydroxychloroquine, Vorinostat
NCT02586207
Pembrolizumab in Combination With CRT for LA-SCCHN
Head and Neck Cancer, Squamous Cell Carcinoma
P1
Completed59Open-labelpembrolizumab (MK-3475), Cisplatin
NCT06643377
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Healthy, Renal Impairment
P1
Completed27Open-labelEnlicitide
NCT02715700
Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)
Human Immunodeficiency Virus (HIV) Infection
P1
Completed14Open-labelMethadone, Doravirine
NCT00535236
A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
Herpes Zoster, Herpes Zoster-related Complications
P1
Completed341RCT, Double-blindV212, Placebo
NCT07086079
A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)
Healthy
P1
Completed12Open-labelDOR/ISL
NCT04722562
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
Heart Failure
P1
Completed27Open-labelVericiguat (BAY1021189)
NCT01327313
A Study of EMD525797 in Solid Tumor Patients in Japan
Solid Tumor
P1
Completed27Open-labelEMD525797, EMD525797, EMD525797, EMD525797
NCT02392494
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
Hepatitis C
P1
Completed9Open-labelMK-1075
NCT04609579
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Advanced Solid Tumor, Advanced Lymphoma
P1
Terminated27Open-labelSNX281, pembrolizumab
NCT04224480
Longitudinal Immune-phenotyping of HCC Following MK-3475
Hepatocellular Carcinoma
P1
Unknown8Open-labelPembrolizumab
NCT00704054
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
Solid Tumors
P1
Completed15Open-labelridaforolimus
NCT02938624
Anti PD-1 Neo-adjuvant Treatment for NSCLC
Non Small Cell Lung Carcinoma, Stage I
P1
Completed28Open-labelPembrolizumab 200 mg IV single dose, Pembrolizumab 200 mg IV twice interval 21 days, Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d, Pembrolizumab 100 mg I.V single dose
NCT06733688
A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)
Healthy
P1
Completed36RCT, Open-labelTedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
NCT02938273
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
Carcinoma, Squamous Cell of Head and Neck
P1
Completed10Open-labelavelumab, cetuximab
NCT06687759
A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
Healthy
P1
Completed8Open-label[14C]Calderasib
NCT06816030
A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
Healthy
P1
Completed16Open-labelMK-4482
NCT03261401
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
Healthy
P1
Completed88RCT, Double-blindM5717, Placebo, M5717
NCT03996473
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Carcinoma, Non-Small-Cell Lung
P1
Terminated8RCT, Open-labelRadium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
NCT06609161
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
Healthy
P1
Completed18RCT, Open-labelTedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
NCT01390441
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
Rheumatoid Arthritis
P1
Terminated100RCT, Double-blindMK-8808, MabThera® (rituximab), Methotrexate, Rituxan® (rituximab), Methylprednisolone, Acetaminophen, Loratadine
NCT00393445
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
Hyperglycemia
P1
Completed6RCT, Single-blindGLP-1 control, GLP-1 and Exendin(9-39) 300, saline control, GLP-1 and Exendin(9-39) 600, GLP-1 and Exendin(9-39) 900, GLP-1 and Exendin(9-39) 1200
NCT04370873
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
Pulmonary Hypertension
P1
Completed22RCT, Double-blindFrespaciguat, Placebo
NCT03311841
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
Renal Insufficiency
P1
Completed32Open-labelMidazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin
NCT00561418
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Lymphoma, Small Intestine Cancer
P1
Completed23Open-labelvorinostat
NCT00848718
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Locally Advanced, Metastatic Solid Tumors
P1
Completed77Open-labelMK-2206, docetaxel, erlotinib, carboplatin, paclitaxel, corticosteroid
NCT00570310
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
Neuralgia, Postherpetic, Diabetic Neuropathy
P1
Completed104RCT, Double-blindComparator: pregabalin, Comparator: Placebo (unspecified)
NCT05656040
A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
End-Stage Renal Disease, End-Stage Kidney Disease
P1
Completed14RCT, Single-blindMK-2060, Placebo
NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Locally Advanced Solid Tumor, Metastatic Cancer
P1
Terminated100Open-labelCTX-471, Pembrolizumab (KEYTRUDA®)
NCT01054300
Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)
Diabetes Mellitus, Type 2, Adult
P1
Completed52RCT, Double-blindErtugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose, Ertugliflozin 4 mg split into twice daily, Placebo
NCT01071018
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Solid Tumors
P1
Completed24Open-labelMK2206 every other day, MK2206 once weekly
NCT02314923
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola Virus
P1
Completed513RCT, Double-blindV920 Vaccine
NCT03629223
Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib
Healthy
P1
Completed66RCT, Open-labelTepotinib TF2, Tepotinib TF3
NCT01396005
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
Hepatitis C Virus
P1
Completed21Open-labelboceprevir, methadone, buprenorphine/naloxone
NCT06894771
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Malignant Neoplasm
P1
Completed5Open-labelMK-4700, Pembrolizumab
NCT00768170
MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)
Asthma
P1
Completed10Open-labelMK0633
NCT03546608
Tepotinib Hepatic Impairment Trial
Hepatic Impairment
P1
Completed18Open-labelTepotinib
NCT00701389
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Migraine Disorders
P1
Completed24RCT, Double-blindtelcagepant potassium, sumatriptan, sumatriptan placebo, telcagepant potassium placebo
NCT01948986
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
Renal Impairment, Type 2 Diabetes Mellitus
P1
Completed36Open-labelErtugliflozin
NCT00911469
Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement
Knee Osteoarthritis
P1
Completed73RCT, Double-blindAS902330, Placebo
NCT00863590
A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers
Osteoporosis
P1
Completed24RCT, Double-blindodanacatib, Comparator: odanacatib (Panel B), Comparator: odanacatib (Panel C), Comparator: odanacatib (Panel D)
NCT02630823
MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer, Endometrial Carcinoma
P1
Completed10Open-labelMK-3475, Paclitaxel (standard of care), Carboplatin (standard of care)
NCT01504165
Pharmacokinetics in Subjects With Renal Impairment
Renal Impairment
P1
Completed32Open-labelcilengitide 2000mg, cilengitide 2000mg, cilengitide 2000mg, cilengitide 1000mg, cilengitide > 1000mg and up to 2000mg
NCT00511667
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
Type 2 Diabetes Mellitus
P1
Completed70RCT, Double-blindMK0941, Comparator: Placebo
NCT04336098
Study of SRF617 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
P1
Completed85Open-labelSRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
NCT00836498
A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)
Rotavirus
P1
Terminated66RCT, Double-blindComparator: RotaTeq, Comparator: Placebo, Comparator: RotaTeq + Placebo
NCT00696709
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
Herpes Zoster
P1
Completed290RCT, Double-blindComparator: V212, Comparator: Placebo
NCT00565006
A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)
Ambulatory Blood Pressure
P1
Completed22—MK0859
NCT00857311
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
Hepatitis C
P1
Completed17RCT, Double-blindMRKAd5 HIV-1 gag vaccine (V520), Comparator: Placebo, Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed, MRKAd5 HIV-1 gag vaccine (V520)
NCT06647628
A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)
Healthy
P1
Completed16RCT, Double-blindMK-1708, Placebo
NCT03745144
Effects of Cladribine Tablets on the PK of Microgynon®
Relapsing Multiple Sclerosis (RMS)
P1
Completed28RCT, Double-blindCladribine, Placebo, Microgynon®
NCT01390428
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)
Hepatitis C
P1
Completed50Open-labelGrazoprevir
NCT01335607
A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)
Hepatitis C
P1
Completed12RCT, Open-labelSamatasvir tablet, Samatasvir capsule
NCT04659629
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Solid Tumor, Advanced Solid Tumor
P1
Completed59Open-labelNL-201, Pembrolizumab Injection [Keytruda]
NCT01512693
Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)
Hepatic Insufficiency
P1
Completed17Open-labelMK-0822
NCT04695847
M1231 in Participants With Solid Tumors
Metastatic Solid Tumors, Esophageal Cancer
P1
Completed23Open-labelM1231, M1231
NCT06442436
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Hepatic Impairment (HI)
P1
Completed24Open-labelNemtabrutinib
NCT02318771
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer
P1
Completed41RCT, Open-labelMK-3475
NCT04730635
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
Alzheimer's Disease, Mild Cognitive Impairment
P1
Completed44RCT, Double-blindDonepezil, Placebo
NCT06625840
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
Healthy
P1
Completed16RCT, Double-blindMK-1167, Placebo
NCT02011490
Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
Renal Insufficiency, Renal Impairment
P1
Completed33Open-labelsugammadex
NCT05311618
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Pancreatic Cancer, Breast Cancer
P1
Unknown71Open-labelNGM438, Pembrolizumab (KEYTRUDA ®)
NCT01118676
Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Locally Advanced Non Small Cell Lung Cancer (NSCLC)
P1
Completed14Open-labelcilengitide, radiochemotherapy
NCT04037748
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Healthy
P1
Completed72RCT, Open-labelPuran T4®, Eutirox®
NCT01209741
Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)
Migraine
P1
Completed48RCT, Open-labeltelcagepant potassium, MK-0974 5Mo5C, MK-0974 12Mo5C
NCT00541229
Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)
Type 2 Diabetes
P1
Completed103RCT, Double-blindsitagliptin phosphate, sitagliptin phosphate, Comparator: Placebo
NCT00418366
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
Renal Insufficiency, Hemodialysis
P1
Completed24Open-labelMK0431, sitagliptin phosphate / Duration of Treatment : 1 Days
NCT00112372
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
Cancer
P1
Completed147RCT, Open-labelRidaforolimus
NCT01678807
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
P1
Completed195RCT, Double-blindMK-8237 6 DU, MK-8237 12 DU, Placebo
NCT00966030
Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)
Migraine
P1
Completed50RCT, Open-labelMK0974 tablet, Comparator: MK0974 liquid filled capsule
NCT07677163
A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)
Healthy
P1
Completed15RCT, Open-labelMK-1403 formulation (FM) 1 + additive, MK-1403 FM2 + additive
NCT01025791
A Single Dose Study of MK-8266 (MK-8266-001)
Hypertension
P1
Completed25RCT, Double-blindMK-8266 0.1 mg, MK-8266 1.0 mg, Placebo
NCT00100152
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
P1
Terminated50Open-labelMK0752, (Notch Inhibitor)
NCT01593735
A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)
Hepatitis C
P1
Completed30RCT, Double-blindMK-2748, Placebo
NCT02675946
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Solid Tumors, GI Cancer
P1
Unknown72Open-labelCGX1321, Pembrolizumab, encorafenib, cetuximab
NCT01348880
Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study
Erectile Dysfunction
P1
Completed42RCT, Double-blindVardenafil ODT, (Staxyn, BAY38-9456), Placebo
NCT04647708
Study of M5049 in CLE and SLE Participants
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
P1
Completed25RCT, Double-blindM5049, M5049, M5049, Placebo
NCT07232589
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
Healthy
P1
Completed26Open-labelNemtabrutinib, Diltiazem
NCT01324440
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
Staphylococcal Infections
P1
Completed64RCT, Double-blindV710 (30 µg) with MAA, V710 (30 µg) without MAA
NCT05064488
Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
Healthy
P1
Completed40Open-labelEvobrutinib (45mg), Digoxin (0.25mg), Metformin (10mg), Rosuvastatin (10mg), Sumatriptan (25mg)
NCT03566810
Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)
Healthy
P1
Completed54RCT, Open-labelTest GXR, Reference GXR
NCT04920383
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Advanced Solid Tumor, Lymphoma
P1
Terminated29Open-labelALPN-202, pembrolizumab KEYTRUDA®
NCT01329913
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
Hepatitis C
P1
Completed36RCT, Double-blindMK-6325, Placebo to MK-6325, MK-6325, Placebo to MK-6325, MK-6325, Placebo to MK-6325
NCT01075451
Antimicrobial Drug Use and Resistant Staphylococcus Aureus
Staphylococcus Aureus
Completed41——
NCT03317366
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS)
NO_LONGER_AVAILABLE——ARQ 092
NCT07487441
Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Not Yet Recruiting30——
NCT01143259
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
Ileus
N/A
Completed274RCT, Double-blindAlvimopam, 300 mg Polyethylene
NCT00492193
Early Post-Op Recovery After Partial Large Bowel Resection
Diverticulitis, Colon Polyps
Completed139——
NCT01150760
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Ileus
Completed7,050—Alvimopan
NCT01025271
Cerebrospinal Fluid Pharmacokinetics of Daptomycin
Meningitis
N/A
Terminated2Open-labelDaptomycin
NCT01216540
Vancomycin-Associated Nephrotoxicity
Nephrotoxicity
Completed398——
NCT02888197
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
Candidiasis, Vulvovaginal, Yeast Infection
Completed32——
NCT02762721
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma
Completed131——
NCT01813500
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
Crohn's Disease, Ulcerative Colitis
Completed400——
NCT07878442
Tailored Vaccine Messaging for Parents/Caregivers of Adolescents
Vaccine Confidence, Adolescent Vaccination
N/A
Not Yet Recruiting2,000RCT, Open-label—
NCT02097953
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Drug Interactions, Pharmacokinetics
Early P1
Completed12Open-labelDaptomycin, Rifampin
NCT00261807
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections
N/A
Completed25Open-labelDaptomycin 6mg/kg/day
NCT01012089
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
Chronic Kidney Disease, Bacterial Infection
N/A
Completed6Open-labelDaptomycin
NCT02597790
A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
HIV, Hepatitis C
Completed87——
NCT01671605
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
Chronic Kidney Disease, Cardiovascular Disease
Completed103——
NCT00725010
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Glioblastoma
Completed64—Temozolomide
NCT00723827
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Glioblastoma, Glioma
Completed682—Temozolomide
NCT00725842
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
Hepatitis C, Hepatitis C, Chronic
Terminated97—Peg-IFN alfa-2b, Ribavirin
NCT04167761
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Cardiovascular Diseases, Atherosclerosis
Early P1
Completed61Open-labelErtugliflozin
NCT01142453
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
Relapsing-Remitting Multiple Sclerosis
Completed231—Interferon beta 1a
NCT00658827
Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis
Inflammatory Bowel Disease
Completed370——
NCT06639386
Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups
Vaccine Hesitancy, Vaccine Refusal
Completed68——
NCT01355003
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
Papillomavirus Infections
Terminated1,080——
NCT01164605
Pilot Study of Raltegravir Lipodystrophy IISP
HIV Infection
N/A
Unknown30Open-labelRaltegravir
NCT01643473
Tailored Approaches to Improve Medication Adherence
Hypertension
N/A
Completed42RCT, Single-blind—
NCT03854734
Healthy, Immunized Communities Study
Vaccine Hesitancy, Communicable Diseases in Children
N/A
Completed148RCT, Single-blind—
NCT00705614
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
Crohn's Disease
Completed2,662—Remicade
NCT01517529
Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
Hepatitis C
Completed10——
NCT00704522
Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)
Hepatitis C, Chronic, Hepacivirus
Completed601—Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
NCT04259931
PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA
Clostridium Difficile Infection
Unknown50——
NCT01382407
Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab
Colorectal Cancer Metastatic
Completed100—Cetuximab
NCT07348250
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
Parkinson's Disease (PD), Parkinson's Disease
Early P1
Terminated16Open-label[18F]MK-0947
NCT01293123
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals
HIV
N/A
Terminated2RCT, Open-labelRaltegravir, Efavirenz
NCT00772473
Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine
Headache, Migraine
Completed34——
NCT01632254
Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque
Atherosclerosis
Unknown30——
NCT00904644
Raltegravir in the Swiss HIV Cohort Study
HIV Infection
Completed200—Raltegravir
NCT00588471
Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention
Coronary Artery Disease
N/A
Terminated57RCT, Double-blindSimvastatin, Placebo
NCT04196777
Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists
Urologic Diseases, Antibacterial Drug Adverse Reaction
N/A
Completed525Open-label—
NCT06704308
Parents' HPV Stories
HPV Vaccination
N/A
Not Yet Recruiting58Open-label—
NCT00724854
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
Hepatitis C, Chronic, Hepatitis C
Completed1,146—PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
NCT00724373
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
Hepatitis C, Chronic
Completed442—Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
NCT01423760
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
Non-Small Cell Lung Cancer, Multiple Myeloma
N/A
Terminated27Open-labelTecemotide
NCT00723710
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Melanoma
Completed299—Intron A (interferon alfa-2b; SCH 30500)
NCT01065766
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
Type 2 Diabetes Mellitus
Completed4,065—Sitagliptin/metformin
NCT01472575
Impact of Rotavirus Vaccine Introduction for South Australian Children
Viral Gastroenteritis Due to Rotavirus, Gastroenteritis
Unknown1,200——
NCT04947111
Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
Dengue
N/A
Unknown1,960Open-label—
NCT02496832
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
Pancreatic Adenocarcinoma, Advanced Disease
N/A
Withdrawn—Open-label18F-Fluoroazomycin arabinoside
NCT01293656
Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)
Inflammatory Bowel Disease, Crohn's Disease
Withdrawn———
NCT00394602
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Gastric Cancer, Pancreatic Cancer
Terminated207——
NCT00723879
Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)
Hepatitis C, Chronic, Hepacivirus
Terminated115—Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
NCT01134640
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
Metastatic Colorectal Cancer
Completed286——
NCT01836718
Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation
Hepatitis C Virus, Liver Transplantation
Unknown20——
NCT02599220
Clinical Outcomes and Cost of Gram Negative Bacteremia
Gram-negative Bacteremia, Bacteremia
Completed2,000——
NCT01581710
Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.
Mild Persistent Asthma
N/A
Completed32RCT, Double-blindMontelukast to placebo, Placebo to montelukast
NCT01986686
Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis
Diverticulitis
N/A
Completed107RCT, Open-label—
NCT00641641
The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
HIV Infection
N/A
Completed16Open-labelTenofovir + emtricitabine + raltegravir.
NCT00572832
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
Human Papillomavirus Infection
N/A
Completed200RCT, Open-labelQuadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
NCT00723632
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
Hepatitis C, Chronic, Hepatitis C
Completed901—peginterferon alfa-2b, ribavirin
NCT04934800
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
Multiple Sclerosis
Completed256—Cladribine
NCT01174147
A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)
Candidemia
Completed436——
NCT01349920
Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
Crohn Disease
Completed15—Infliximab
NCT03883568
A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenotypes of Knee Osteoarthritis
Knee Osteoarthritis
Completed297——
NCT00738725
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
Plaque, Atherosclerotic Disease
Completed7,687——
NCT01173068
An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.
Urinary Tract Infections
Unknown60—Ertapenem
NCT01087073
Improving Diabetes Care and Outcomes on the South Side of Chicago
Diabetes Mellitus
N/A
Completed6,209Open-label—
NCT01814722
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Human Immunodeficiency Virus
Terminated63——
NCT01085916
Prevalence of Asthma and Rhinitis Symptoms Among Secondary School Students in Saudi Arabia
Asthma, Rhinitis
Unknown4,000——
NCT01062048
Januvia Re-examination Study (MK-0431-181)
Type 2 Diabetes Mellitus
Completed3,483—Sitagliptin, Sulfonylurea, Insulin
NCT05761509
"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"
HIV Infections
Completed226—Doravirine
NCT03244176
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study
Lymphomas Non-Hodgkin's B-Cell
Early P1
Completed28Open-labelAvelumab
NCT00421018
Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)
Allergic Asthma
N/A
Completed187RCT, Double-blindSingle corticosteroid inhalers and Singulair
NCT00430287
Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?
Open Angle Glaucoma
Completed101——
NCT00704717
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
Hepatitis C, Chronic, Hepatitis C
Completed185—PegIntron (peginterferon alfa-2b; SCH 54031) pen, Rebetol (ribavirin; SCH 18908)
NCT01617018
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
Psoriasis
Completed4,613——
NCT01110993
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Multiple Sclerosis, Relapsing-Remitting
Completed65——
NCT01133509
A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
Genital Human Papilloma Virus Infection
N/A
Unknown100Open-labelGardasil
NCT01109108
Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
Nasopharyngeal Carriage of S. Pneumoniae
Completed9,000——
NCT02194608
Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)
Type 2 Diabetes Mellitus
N/A
Completed500RCT, Open-label—
NCT01138813
Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)
Glioma
Completed8——
NCT01476150
Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population
Osteoporosis
Unknown10,000——
NCT03394196
RESIST-2: 2nd-line ART for HIV-2 Infection
HIV-2 Infection
N/A
Terminated152Open-label2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)
NCT01718860
Effects of Postoperative Residual Paralysis on Hospital Costs
Residual Paralysis, Post-Anesthesia
Unknown3,000——
NCT00562991
Monitoring Asthma Treatment Using Exhaled Nitric Oxide
Asthma
Completed99——